Loading
Overweight Or Obesity / Osteoarthritis / Eloralintide · Phase 3 Trial
ClinicalTrials.gov · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a recruiting Phase 3 trial of eloralintide versus placebo in adults with knee osteoarthritis pain and overweight or obesity, with primary endpoints of body weight change and WOMAC pain score at week 64. No efficacy or safety results are currently available in this registry record.
Phase 3, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Osteoarthritis, Overweight or Obesity; age from 18 Years. Intervention: Eloralintide (YOA1); Eloralintide (YOA2). Compared with: Placebo (YOA1) — Placebo Comparator; Placebo (YOA2) — Placebo Comparator. n = 900. 152 sites across 14 countries.
This is a recruiting Phase 3 trial of eloralintide versus placebo in adults with knee osteoarthritis pain and overweight or obesity, with primary endpoints of body weight change and WOMAC pain score at week 64. No efficacy or safety results are currently available in this registry record.
This is a registry record; no efficacy or safety results are reported
The source did not state who this applies to in practice.
This is a recruiting Phase 3 trial registration with no results posted; the study design and primary endpoints are defined but outcomes remain unreported.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07353931). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 900 participants (ESTIMATED). Conditions: Osteoarthritis, Overweight or Obesity. Interventions: DRUG: Eloralintide; DRUG: Placebo. Primary outcome measures: Percent Change from Baseline in Body Weight , Baseline, Week 64; Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score , Baseline, Week 64. Brief summary: The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.